Form 4: Haemonetics EVP and General Counsel Michelle Basil Reports Stock Transactions

Michelle Basil, EVP and General Counsel of Haemonetics, reports multiple transactions involving common stock, including sales, acquisitions, and tax-related withholdings, as well as the acquisition of non-qualified stock options.

Summary

• Michelle Basil, EVP and General Counsel of Haemonetics Corp, filed a Form 4 detailing changes in beneficial ownership.
• On May 17, 2024, Basil sold 1,073 shares of common stock at $95 per share and another 1,604 shares on May 20, 2024 at $95.08 per share, both transactions were pursuant to a pre-existing 10b5-1 trading plan.
• Also on May 17, 2024, 669 shares were withheld for tax obligations related to vesting RSUs at a price of $95.73.
• On the same day, Basil acquired 4,178 shares in the form of RSUs under the company's incentive plan.
• Basil also acquired 9,183 non-qualified stock options with an exercise price of $95.73, vesting in annual increments of 25% beginning May 17, 2025.
• Following these transactions, Basil beneficially owns 31,257 shares of common stock and 9,183 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are a mix of sales (under a pre-existing plan) and acquisitions (RSUs and options), suggesting a balanced view of the company's prospects.

Positives

• The acquisition of 4,178 RSUs indicates continued alignment with the company's long-term performance.
• The grant of 9,183 non-qualified stock options incentivizes future performance.

Negatives

• The sale of 2,677 shares may be perceived negatively, although it was executed under a pre-existing 10b5-1 trading plan.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes be misinterpreted by the market.
• Tax obligations related to vesting RSUs could lead to further stock sales.

Future Outlook

The reporting person's future transactions may be influenced by the existing 10b5-1 trading plan and the vesting schedule of RSUs and stock options.

Industry Context

Executive stock transactions are common and closely monitored by investors for insights into management's perspective on the company's value and future prospects. Transactions under 10b5-1 plans are generally viewed as less indicative of current sentiment.

Comparison to Industry Standards

• Executive compensation packages at comparable companies like Baxter International and Medtronic often include a mix of salary, stock options, and RSUs.
• The vesting schedules and terms of these equity grants are generally in line with industry standards to incentivize long-term performance.
• Sales under 10b5-1 plans are a common practice among executives to manage personal finances and avoid accusations of insider trading.

Stakeholder Impact

• Shareholders may scrutinize the stock sales for insights into executive sentiment.
• Employees may view the RSU and option grants as positive signals of the company's commitment to employee compensation.

Next Steps

• Monitor future Form 4 filings by the reporting person for further transactions.
• Track the vesting of RSUs and stock options.

Key Dates